CEO: Katrine Bosley

Advent Contact: Raj Parekh

Covalent small molecule drug discovery platform

Avila developed a novel chemistry approach 'Avilomics' to discover oral small molecule covalent inhibitors of proteases and kinases. Avilomics allows the design of highly specific compounds that irreversibly bind to the protein target to improve therapeutic index and clinical efficacy. Avila’s most advanced product candidate, AVL-292, a highly selective Btk inhibitor was in Phase I clinical development at the time of its acquisition by Celgene.

Advent invested in the Series A in 2007. Avila was acquired by Celgene in 2012 for $925m in cash and milestones.